Peptide Profile
Leuprolide
Lupron · Leuprorelin · leuprolide acetate
Leuprolide (leuprorelin; Lupron) is a synthetic nonapeptide GnRH agonist (D-Leu6, des-Gly10-GnRH ethylamide) designed as a superagonist of the gonadotropin-releasing hormone receptor; paradoxically, its continuous non-pulsatile…
- Routes
- subcutaneous, intramuscular, implant
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What Leuprolide is
About Leuprolide
Continuous GnRH receptor stimulation causes receptor desensitization and downregulation. This suppresses LH/FSH → testosterone/estrogen to castrate levels. Short-term pulsatile use can transiently stimulate the axis before suppression occurs.
Leuprolide (leuprorelin; Lupron) is a synthetic nonapeptide GnRH agonist (D-Leu6, des-Gly10-GnRH ethylamide) designed as a superagonist of the gonadotropin-releasing hormone receptor; paradoxically, its continuous non-pulsatile receptor occupation produces profound hypogonadotropism by causing receptor downregulation and pituitary desensitization — the opposite effect of endogenous pulsatile GnRH release — resulting in medical castration levels of sex steroids. Continuous LHRH receptor agonism initially produces a testosterone or estrogen flare before pituitary downregulation suppresses LH and FSH secretion, reducing testosterone to castrate levels in men and estrogen to postmenopausal levels in women within 2–4 weeks; this chemical hypogonadism forms the basis for its use across hormone-sensitive conditions including prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. A landmark randomized controlled trial published in the New England Journal of Medicine compared leuprolide against diethylstilbestrol for metastatic prostate cancer and demonstrated equivalent efficacy with a markedly superior cardiovascular side-effect profile, establishing the pivotal evidence base that led to FDA approval and positioned GnRH agonists as the preferred hormonal therapy for prostate cancer. Leuprolide (Lupron, AbbVie; and generic formulations) is FDA-approved and requires a prescription; approved indications include advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and other hormone-sensitive conditions; it is available as daily subcutaneous injection, monthly depot, and multi-month depot formulations.
Women's Health
Leuprolide is FDA-approved for endometriosis and uterine fibroids (systematic review/meta-analysis + pivotal RCT evidence) and used in IVF protocols. Its continuous GnRH-agonist mechanism deliberately induces a temporary menopause-like hypoestrogenic state, producing hot flashes and measurable bone loss in RCT data — it does not treat menopausal symptoms, it causes a menopause-like state as a side effect of its therapeutic mechanism. It can worsen mood (studied via an HPA-probe RCT) and carries a pregnancy contraindication (fetal harm) on its FDA label.
Leuprolide Benefits & Research Areas
What the evidence says about Leuprolide
Research Evidence
based on 8 studies · 3 RCTs · most recent 2026
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- FDA Approved
- Effective Date
- April 8, 1985
- Source
- View FDA source →
FDA-approved: Lupron (leuprolide acetate), Drugs@FDA application 019010.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
8 sources cited · 4 strong · 2 moderate · 2 weak
3 RCTs · 1 Meta-analysis · 2 Cohorts · 2 Animals
The Effect of Hormonal Treatment on Ovarian Endometriomas: A Systematic Review and Meta-Analysis
J Minim Invasive Gynecol · 2024
SR/MA (16 studies, 888 women) including leuprolide among effective hormonal treatments for endometriomas.
Add-back estradiol/progesterone to GnRH agonist in PMDD
Am J Obstet Gynecol · 2009
Double-blind crossover RCT (n=27) using leuprolide as an experimental HPA/mood probe in PMDD.
Depot leuprolide vs danazol for endometriosis: multicenter double-blind RCT
Am J Obstet Gynecol · 1993
Multicenter RCT (n=270) documenting leuprolide efficacy alongside induced bone loss + vasomotor effects.
Show 5 more sources ↓
Leuprolide versus diethylstilbestrol for metastatic prostate cancer
New England Journal of Medicine · 1984
In the landmark phase 3 randomized controlled trial of 199 patients, leuprolide (1 mg/day subcutaneous) achieved 86% objective response (equivalent to DES 85%) in previously untreated metastatic prostate cancer, with comparable testosterone and acid phosphatase suppression but significantly fewer adverse events (gynecomastia, nausea, edema, thromboembolism) than diethylstilbestrol, establishing GnRH agonism as the preferred androgen deprivation strategy.
Utility of a 40-minute LH level after depot leuprolide for diagnosis and treatment monitoring in girls with CPP.
J Endocrinol Invest · 2026
# Summary Research found that measuring luteinizing hormone (LH) levels 40 minutes after leuprolide injection provides comparable diagnostic accuracy to the standard GnRH stimulation test for assessing gonadotropic activation in girls with central precocious puberty. This study demonstrated that the post-leuprolide LH measurement could serve as a practical alternative for both initial diagnosis and treatment monitoring in settings where GnRH testing is unavailable.
Surpassing genetic height potential at final adult height after monthly depot leuprolide therapy in Taiwanese girls with central precocious or early puberty: a ROC-based analysis.
Front Pediatr · 2026
# Research Summary Research found that leuprolide therapy in Taiwanese girls with central precocious puberty enabled approximately half of the treated patients to achieve final adult heights exceeding their genetically predicted mid-parental height, with those starting treatment earlier and showing greater bone age advancement demonstrating the most favorable outcomes. This study demonstrated that while leuprolide therapy supports improved height outcomes in select patients, individualized assessment based on skeletal maturity and growth patterns during treatment is essential for prognostic evaluation.
Terazosin as a Non-Hormonal Treatment for Endometriosis.
Int J Mol Sci · 2026
# Summary Research found that terazosin, a non-hormonal medication, reduced multiple inflammatory markers and oxidative stress in endometriotic lesions in a rat model with effectiveness comparable to leuprolide, a standard hormonal treatment. This study demonstrated that terazosin achieved these anti-inflammatory and anti-angiogenic effects without hormonal suppression, suggesting potential as an alternative therapeutic approach that warrants further clinical investigation.
Effects of Surgical and Medical Androgen Deprivation on Bladder Remodeling and Steroid Receptor Expression: An Experimental Rat Study.
Neurourol Urodyn · 2026
Leuprolide Side Effects & Safety Considerations
Research-use compound with limited human data. Evidence strength varies — see the Evidence section.
Absolute contraindications
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Common monitoring markers in research protocols
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSLeuprolide
Frequently Asked Questions — Leuprolide
Leuprolide (leuprorelin; Lupron) is a synthetic nonapeptide GnRH agonist (D-Leu6, des-Gly10-GnRH ethylamide) designed as a superagonist of the gonadotropin-releasing hormone receptor; paradoxically, its continuous non-pulsatile receptor occupation produces profound hypogonadotropism by causing receptor downregulation and pituitary desensitization — the opposite effect of endogenous pulsatile GnRH release — resulting in medical castration levels of sex steroids. Continuous LHRH receptor agonism initially produces a testosterone or estrogen flare before pituitary downregulation suppresses LH and FSH secretion, reducing testosterone to castrate levels in men and estrogen to postmenopausal levels in women within 2–4 weeks; this chemical hypogonadism forms the basis for its use across hormone-sensitive conditions including prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.
HPG axis modulation, testosterone suppression, hormonal restart, GnRH axis control.
Research on Leuprolide primarily documents effects related to HPG axis modulation and testosterone suppression and hormonal restart and GnRH axis control. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
For Leuprolide, its FDA status is FDA-approved, and it is available by prescription. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
1 provider in the directory currently offers Leuprolide.
SR/MA (16 studies, 888 women) including leuprolide among effective hormonal treatments for endometriomas.
How to get Leuprolide
Where to buy Leuprolide
1 providerClinics
1 providerQuestions to ask your provider
Stay updated on Leuprolide providers
New providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.